Zahedan Journal of Research in Medical Sciences

Published by: Kowsar

Effect of Pentoxifylline on Recurrence in Patients With Multiple Sclerosis: A Non-Randomized Double-Blinded Placebo Controlled Clinical Trial

Akbar Hamzei Moghaddam 1 , Rostam Seiffaddini 1 , Asma Najafzadeh 1 , * , Hossien Ali Ghaffaripour 2 , Peyman Arasteh 3 , Zeinab Movahhedi 4 and Narges Khanjani 1
Authors Information
1 Department of Neurology, Neurology Research Center, Kerman University of Medical Sciences, Kerman, IR Iran
2 Pediatric Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Students Research Committee, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 PhD Student of Nursing, Department of Nursing, Kerman University of Medical Sciences, Kerman, IR Iran
Article information
  • Zahedan Journal of Research in Medical Sciences: November 28, 2015, 17 (11); e2227
  • Published Online: November 1, 2015
  • Article Type: Research Article
  • Received: April 16, 2014
  • Accepted: June 10, 2014
  • DOI: 10.17795/zjrms-2227

To Cite: Hamzei Moghaddam A, Seiffaddini R, Najafzadeh A, Ghaffaripour H A, Arasteh P, et al. Effect of Pentoxifylline on Recurrence in Patients With Multiple Sclerosis: A Non-Randomized Double-Blinded Placebo Controlled Clinical Trial, Zahedan J Res Med Sci. 2015 ; 17(11):e2227. doi: 10.17795/zjrms-2227.

Copyright © 2015, Zahedan University of Medical Sciences.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Lublin FD, Miller AE. Neurology in clinical practice. 2008; : 1583-608
  • 2. Riley CS, Tullman MJ. Merritt's neurology. 2010; : 904-7
  • 3. Ropper AH, Samuels MA. Adams & Victor's Principles of Neurology. 2009; : 874-95
  • 4. van Oosten BW, Rep MH, van Lier RA, Scholten PE, von Blomberg BM, Pflughaupt KW, et al. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J Neuroimmunol. 1996; 66(1-2): 49-55[PubMed]
  • 5. Olsson T. Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol. 1992; 40(2-3): 211-8[PubMed]
  • 6. Selmaj KW, Raine CS. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol. 1988; 23(4): 339-46[DOI][PubMed]
  • 7. Puccioni-Sohler M, Rieckmann P, Kitze B, Lange P, Albrecht M, Felgenhauer K. A soluble form of tumour necrosis factor receptor in cerebrospinal fluid and serum of HTLV-I-associated myelopathy and other neurological diseases. J Neurol. 1995; 242(4): 239-42[PubMed]
  • 8. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand. 1988; 78(4): 318-23[PubMed]
  • 9. Wang X, Ma C, Wu J, Zhu J. Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barre syndrome as well as their animal models. J Neurosci Res. 2013; 91(7): 871-81[DOI][PubMed]
  • 10. Tumani H, Kassubek J, Hijazi M, Lehmensiek V, Unrath A, Sussmuth S, et al. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate. Eur Neurol. 2011; 65(3): 164-9[DOI][PubMed]
  • 11. Awad AM, Stuve O. Immunopathogenesis of multiple sclerosis: new insights and therapeutic implications. Continuum (Minneap Minn). 2010; 16(5 Multiple Sclerosis): 166-80[DOI][PubMed]
  • 12. Rieckmann P, Weber F, Gunther A, Martin S, Bitsch A, Broocks A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol. 1996; 64(2): 193-200[PubMed]
  • 13. All about multiple sclerosis: MS news and information on diagnosis, symptoms, and treatments. 2011;
  • 14. Bisaga GN, Odinak MM, Boiko AN, Mel'nik Iu B, Popova NF. [Possibilities of treatment of multiple sclerosis exacerbations without corticosteroids: a role of metabolic and antioxidant therapy]. Zh Nevrol Psikhiatr Im S S Korsakova. 2011; 111(2): 44-8[PubMed]
  • 15. Weber F, Polak T, Gunther A, Kubuschok B, Janovskaja J, Bitsch A, et al. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol. 1998; 44(1): 27-34[DOI][PubMed]
  • 16. Jafarzadeh A, Ebrahimi HA, Bagherzadeh S, Zarkesh F, Iranmanesh F, Najafzadeh A, et al. Lower serum levels of Th2-related chemokine CCL22 in women patients with multiple sclerosis: a comparison between patients and healthy women. Inflammation. 2014; 37(2): 604-10[DOI][PubMed]
  • 17. Pede PD, Visintini D, Telera A, Cucurachi L, Campanini C, Immovilli P, et al. Immunomodulatory effects of IFN-beta1a treatment alone or associated with pentoxifylline in patients with relapsing-remitting multiple sclerosis (RRMS). J Interferon Cytokine Res. 2005; 25(8): 485-9[DOI][PubMed]
  • 18. Odinak MM, Bisaga GN, Zarubina IV. [New approaches to antioxidant therapy in multiple sclerosis]. Zh Nevrol Psikhiatr Im S S Korsakova. 2002; : 72-5[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments